Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Minuti

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Translational Oncology|July 2, 2022
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutationsMatteo Canale, Elisabetta Petracci, Paola Cravero, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2023
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinomaFilippo Tommaso Gallina, Riccardo Tajè, Fabiana Letizia Cecere, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of the American Geriatrics Society|August 21, 2010
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancerAndrea Fontana, Guido Bocci, Luca Galli, et al.
Heliyon|December 17, 2024
Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary groupSabrina Mariotti, Gabriele Minuti, Lorenza Landi, et al.
Recenti Progressi in Medicina|July 1, 2023
[Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.]Gabriele Minuti, Alessio Stefani, Luca Trodella, et al.
Oncotarget|February 8, 2019
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Claudia Ligorio, et al.
ESMO Open|August 21, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort studyEva Blondeaux, Arlindo R Ferreira, Francesca Poggio, et al.
Recenti Progressi in Medicina|October 14, 2021
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]Gabriele Minuti, Alessio Stefani, Silvia Carpano, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Translational Oncology|July 2, 2022
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutationsMatteo Canale, Elisabetta Petracci, Paola Cravero, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancersPierluigi Gasparini, Luciano Cascione, Lorenza Landi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2023
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinomaFilippo Tommaso Gallina, Riccardo Tajè, Fabiana Letizia Cecere, et al.
Oncotarget|May 1, 2018
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)Silvia Vecchiarelli, Francesco Passiglia, Armida D'Incecco, et al.
Journal of the American Geriatrics Society|August 21, 2010
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancerAndrea Fontana, Guido Bocci, Luca Galli, et al.
Heliyon|December 17, 2024
Simultaneous care provision to patients with small cell lung cancer in Lazio region: Practical recommendations of a multidisciplinary groupSabrina Mariotti, Gabriele Minuti, Lorenza Landi, et al.
Recenti Progressi in Medicina|July 1, 2023
[Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.]Gabriele Minuti, Alessio Stefani, Luca Trodella, et al.
Oncotarget|February 8, 2019
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Claudia Ligorio, et al.
ESMO Open|August 21, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort studyEva Blondeaux, Arlindo R Ferreira, Francesca Poggio, et al.
Recenti Progressi in Medicina|October 14, 2021
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]Gabriele Minuti, Alessio Stefani, Silvia Carpano, et al.
Pageof 5